Latest in Cardiology from ACC.org

• New ACC Guidance Addresses Obesity Treatment Strategies Across the CV Spectrum
  As obesity continues to drive cardiovascular risk, the ACC has released two new guidance documents to support clinicians: Concise Clinical Guidance (CCG) on the medical management of obesity and a Scientific Statement focused on treating obesity in adults with heart failure.
• Management of Recurrent Coarctation in Children
  Coarctation of the aorta accounts for 5-8% of all congenital heart disease, with an incidence of approximately four cases per 10,000 live births. It can be seen in isolation or associated with other cardiac lesions.
• Oral, Subcutaneous Amycretin Similarly Safe, Tolerated as GLP-1 Monoagonists
  Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist has a safety and tolerability profile similar with other GLP-1 and amylin agonists in both oral and subcutaneous formulations, according to two studies published in The Lancet.
• CAPLA: Long-Term QOL Improvement With CA For Persistent AFib
  Quality of life (QOL) at three years significantly improved following catheter ablation (CA) for persistent atrial fibrillation (PsAFib), according to a secondary analysis of patients in the CAPLA clinical trial published in JACC: Clinical Electrophysiology.
• Thrombotic Events In ATTR-CM Patients Linked to Primary LA Cardiopathy
  Primary left atrial (LA) cardiopathy appears to be linked to the high risk of thrombotic events (TE) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) independent of atrial fibrillation (AFib), CHA2DS2-VASc score and LA dilatation. This link differs from patients with other left ventricular hypertrophy (LVH) phenotypes according to a new study published in JACC: Cardiovascular […]